by Rod Raynovich | Dec 16, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Investors in healthcare should look deeper into subsectors: biotechnology, devices, diagnostics, drugs and tools As of December 15 the S&P was up 12.94% but the healthcare sector was the laggard up only 0.43%. Compare this to the leaders Consumer Discretionary up...
by Rod Raynovich | Dec 15, 2010 | 2024-25 Life Science Portfolios, BIOgraph
2010 Original Price % Ret. P Price % Recomm 3/29/10 Q2 12/1/10 Ret. Abaxis ABAX 2/2/09 15 79 21.2 27.86 85 CardioV.Sys. CSII 11/5/10 7.15 8.65 21 Celera CRA 3/28/10 7 6.49 5.66 -19 Exact Sci EXAS 12/10/10 5.6 GenProbe GPRO 2/2/09 45 7 46.3 52.77 17 Illumina ILMN...
by Rod Raynovich | Dec 14, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Are investors rotating into the lagging healthcare sector? Biotech, drug and device stocks were up broadly today. The healthcare sector has lagged the market YTD up only 1.35% compared to the S&P up 11.2%. Even major drug stocks, down 2.4% YTD, got strong bids....
by Rod Raynovich | Dec 10, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Tools and Diagnostic stocks are having a good day perhaps sparked by the BeckmanCoulter (BEC) announcement that it is being put up for sale. The BEC stock is up 27% to $72.68.You could have bought Beckman only 3 months ago at $45 after resignation of the CEO and a...
by Rod Raynovich | Dec 6, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Life Science ETF’s: Strategy and Composition There are several ETF’s with biotech and drug positions but the three that are large, liquid and better known with asset values are : First Trust Amex Arca Biotech Index (FBT,$166M) , iShares Nasdaq...
by Rod Raynovich | Dec 1, 2010 | 2024-25 Life Science Portfolios, BIOgraph
SeraCare Reports 40% Increase in Net Income Over Prior Year SeraCare (SRLS) executed six consecutive quarters of successful growth with revenue growth of 13% to $50.4 M for the fiscal year ending SEP 30, compared to revenues of $44.4M year in 2009. Net Income was...
by Rod Raynovich | Nov 30, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Gen-Probe (GPRO,$51.60) announced yesterday that it submitted a Premarket Approval Application(PMA) the the FDA for its APTIMA HPV (human papillomavirus ) assay , a molecular diagnostic test that detects high-risk HPV infections that are associated with cervical...
by Rod Raynovich | Nov 22, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Regeneron(REGN $28) stock soared today on two parallel Phase 3 studies with patients who had neovascular age related macular degeneration(wet AMD), the VEGF Trap Eye drug successfully met the endpoint compared to the current standard of care, ranibizumab dosed every...
by Rod Raynovich | Nov 18, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Exelixis (EXEL) stock was up over 30% today to $6.14 on positive data from two experimental cancer drugs for prostate and ovarian cancer. The XL 184 drug showed promising results with castration-resistant prostate cancer (CRPC) achieving either partial or complete...
by Rod Raynovich | Nov 17, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Microfluidics reported revenues of $4.1M for Q3 2010 ended Sep 30 a decrease of 9% or $500k compared to the same period of 2009. Excluding revenues of $1.3M attributed to machine production of the 2009 H1N1 Flu pandemic, revenues grew 29%.Unit sales increased to 144...
